Resveratrol induces apoptosis in pancreatic cancer cells

Chinese Medical Journal

Volumn 124, Issue 11, 2011, Pages 1695-1699

  Zhou, Jia Hua ^a   Cheng, Hai Yan ^b   Yu, Ze Qian ^a   He, Dao Wei ^a   Pan, Zheng ^a   Yang, De Tong ^a  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Apoptosis; Gene therapy; Pancreatic cancer; Resveratrol

Indexed keywords

CASPASE 3; PROTEIN P21; PROTEIN P53; RESVERATROL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PANCREAS CELL; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL SURVIVAL; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; STILBENES; TUMOR CELLS, CULTURED;

EID: 79957880105     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.11.017     Document Type: Article

References (40)

1. Li D, Abbruzzese JL. New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res 2010; 16: 4313-4318.
2. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010; 10: 368.
3. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-1057.
4. Abbruzzese JL. The challenge of pancreatic cancer. Int J Gastrointest Cancer 2003; 33: 1-2.
5. Tersmette AC, Petersen GM, Offerhaus GJ, Falatko FC, Brune KA, Goggins M, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001; 7: 738-744.
6. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734.
7. Schutte M, da Costa LT, Hahn SA, Moskaluk C, Hoque AT, Rozenblum E, et al. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci U S A 1995; 92: 5950-5954.
8. Liao Q, Hu Y, Zhao YP, Zhou T, Zhang Q. Assessment of pancreatic carcinoma cell chemosensitivity using a three-dimensional culture system. Chin Med J 2010; 123: 1871-1877.
9. Zhang C, Sun JB, Liu DC, Cui YQ, Liu S, Sun HC. Preliminary research on the pathological role of cathepsin-B in subcutaneous heteroplastic pancreatic carcinoma in nude mice. Chin Med J 2009; 122: 2489-2496.
10. Cao G, Wu JX, Wu QH. Low molecular weight heparin suppresses lymphatic endothelial cell proliferation induced by vascular endothelial growth factor C in vitro. Chin Med J 2009; 122: 1570-1574.
11. You L, Chen G, Zhao YP. Core signaling pathways and new therapeutic targets in pancreatic cancer. Chin Med J 2010; 123: 1210-1215.
12. Shi X, Friess H, Kleeff J, Ozawa F, Buchler MW. Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology 2001; 1: 517-524.
13. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001; 61: 4143-4154.
14. Xiong Q, Shi Q, Le X, Wang B, Xie K. Regulation of interleukin-8 expression by nitric oxide in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2001; 21: 529-537.
15. Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. Novel therapies for pancreatic adenocarcinoma. Curr Gastroenterol Rep 2004; 6: 119-125.
16. Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. Novel therapies for pancreatic adenocarcinoma. Curr Oncol Rep 2004; 6: 199-206.
17. MUNCH W. Homeopathic drugs: Veratrum album, the white hellebore. Hippokrates 1957; 28: 315-317.
18. Das DK, Mukherjee S, Ray D. Resveratrol and red wine, healthy heart and longevity. Heart Fail Rev 2010; 15: 467-477.
19. Dudley J, Das S, Mukherjee S, Das DK. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem 2009; 20: 443-452.
20. Hsieh TC, Wu JM. Resveratrol: Biological and pharmaceutical properties as anticancer molecule. Biofactors 2010; 36: 360-369.
21. Li X, Phillips FM, An HS, Ellman M, Thonar EJ, Wu W, et al. The action of resveratrol, a phytoestrogen found in grapes, on the intervertebral disc. Spine (Phila Pa 1976) 2008; 33: 2586-2595.
22. Zhu J, Yong W, Wu X, Yu Y, Lü J, Liu C, et al. Anti-inflammatory effect of resveratrol on TNF-alpha- induced MCP-1 expression in adipocytes. Biochem Biophys Res Commun 2008; 369: 471-477.
23. Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG, Huang YZ. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review). Int J Mol Med 2001; 8: 3-17.
24. Wu JM. Resveratrol alleviates some cardiac dysfunction indexes in an SHR model of essential hypertension. Am J Hypertens 2010; 23: 115.
25. Penumathsa SV, Maulik N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 2009; 87: 275-286.
26. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
27. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-220.
28. Yar AS, Menevse S, Alp E, Helvacioglu F, Take G. The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys. Mol Biol Rep 2010; 37: 2323-2331.
29. Pirola L, Fröjdö S. Resveratrol: one molecule, many targets. IUBMB Life 2008; 60: 323-332.
30. Zykova TA, Zhu F, Zhai X, Ma WY, Ermakova SP, Lee KW, et al. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol Carcinog 2008; 47: 797-805.
31. Huang Z, Wang C, Wei L, Wang J, Fan Y, Wang L, et al. Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun 2008; 374: 517-521.
32. Kundu JK, Chun KS, Kim SO, Surh YJ. Resveratrol inhibits phorbol ester-induced cyclooxygenase-2 expression in mouse skin: MAPKs and AP-1 as potential molecular targets. Biofactors 2004; 21: 33-39.
33. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010; 10: 238.
34. Kai L, Samuel SK, Levenson AS. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int J Cancer 2010; 126: 1538-1548.
35. Chan JY, Phoo MS, Clement MV, Pervaiz S, Lee SC. Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53. Cancer Biol Ther 2008; 7: 1305-1312.
36. Lin HY, Sun M, Tang HY, Simone TM, Wu YH, Grandis JR, et al. Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem 2008; 104: 2131-2142.
37. Alkhalaf M. Resveratrol-induced apoptosis is associated with activation of p53 and inhibition of protein translation in T47D human breast cancer cells. Pharmacology 2007; 80 (2-3): 134-143.
38. Liontas A, Yeger H. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res 2004; 24: 987-998.
39. Narayanan BA, Narayanan NK, Re GG, Nixon DW. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer 2003; 104: 204-212.
40. Soleas GJ, Goldberg DM, Grass L, Levesque M, Diamandis EP. Do wine polyphenols modulate p53 gene expression in human cancer cell lines? Clin Biochem 2001; 34: 415-420.